Published in Am J Med on December 01, 2006
Cancer-associated thrombosis: an overview. Clin Med Insights Oncol (2014) 1.23
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer (2010) 1.10
Comment on "tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients". Thromb Haemost (2013) 1.08
Thrombosis in the critically ill neonate: incidence, diagnosis, and management. Vasc Health Risk Manag (2008) 1.08
Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res (2008) 0.99
The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad Med J (2007) 0.98
Cancer-associated thrombosis: prevention and treatment. Curr Oncol (2008) 0.95
Stroke and Cancer- A Complicated Relationship. J Neurol Transl Neurosci (2015) 0.93
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin. J Vasc Surg (2008) 0.93
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis (2016) 0.91
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer (2009) 0.90
Thrombosis and cancer. Nat Rev Clin Oncol (2012) 0.88
Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence (2014) 0.88
Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. Nat Clin Pract Oncol (2008) 0.87
The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol (2010) 0.87
Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med (2008) 0.86
Essay for the CIHR/CMAJ award: the role of low-molecular-weight heparin therapy venous thromboembolism. CMAJ (2011) 0.85
Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Relat Outcome Meas (2011) 0.85
Management of massive and nonmassive pulmonary embolism. Arch Med Sci (2012) 0.84
Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol (2014) 0.83
Evidence-based guidance on venous thromboembolism in patients with solid tumours. Curr Oncol (2014) 0.83
CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer (2013) 0.82
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. Front Cardiovasc Med (2015) 0.82
Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support Care Cancer (2008) 0.82
Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost (2015) 0.81
Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis. J Gen Intern Med (2016) 0.81
Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One (2014) 0.79
Prevention and treatment of venous thromboembolism in patients with cancer. Can Pharm J (Ott) (2012) 0.79
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis (2016) 0.79
Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol (2015) 0.79
Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. Curr Oncol (2015) 0.78
Recent advances in the management of venous thromboembolism. Korean J Hematol (2010) 0.78
What is the Best Treatment for a Cancer Patient with Thrombosis? Clin Med Insights Oncol (2014) 0.78
Cancer and Venous Thromboembolic Disease: A Review. Oncologist (2017) 0.78
Management of venous thromboembolism: an update. Thromb J (2016) 0.78
Treating venous thromboembolism in patients with cancer. Expert Rev Hematol (2012) 0.77
Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Thrombosis (2011) 0.77
Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? A qualitative study. BMC Med Inform Decis Mak (2012) 0.77
Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Medicine (Baltimore) (2015) 0.77
Acute deep vein thrombosis cases in the real world. Semin Intervent Radiol (2012) 0.76
Multifaceted management of the postthrombotic syndrome. Semin Intervent Radiol (2012) 0.76
Prognosis of patients with suspected pulmonary embolism in Buenos Aires: a prospective cohort study. BMC Pulm Med (2014) 0.75
Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Front Cardiovasc Med (2016) 0.75
Cancer and thrombosis: recent advances. Curr Oncol (2008) 0.75
Management of venous thromboembolism in patients with cancer: role of dalteparin. Vasc Health Risk Manag (2008) 0.75
Prevention and treatment of venous thromboembolism in patients with cancer. Ther Adv Hematol (2012) 0.75
Saddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma. Cardiol Res Pract (2010) 0.75
Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Heliyon (2017) 0.75
Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. Clinicoecon Outcomes Res (2017) 0.75
Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? PLoS One (2015) 0.75
Complex Perioperative Decision-Making: Liver Resection in a Patient with Extensive Superior Vena Cava/Right Atrial Thrombus and Superior Vena Cava Syndrome. Case Rep Anesthesiol (2016) 0.75
The Role of Inferior Vena Cava Filters in Cancer Patients. Semin Intervent Radiol (2016) 0.75
Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures. Semin Intervent Radiol (2015) 0.75
Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin. Clin Appl Thromb Hemost (2015) 0.75
Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs? Br J Clin Pharmacol (2017) 0.75
Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. ESMO Open (2017) 0.75
Thromboembolic disease in cancer patients. Support Care Cancer (2013) 0.75
Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score. Support Care Cancer (2013) 0.75
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med (2015) 7.39
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med (2009) 3.67
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol (2010) 2.75
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Clinical usefulness of home oximetry compared with polysomnography for assessment of sleep apnea. Am J Respir Crit Care Med (2004) 2.28
Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol (2010) 2.00
Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J Virol (2003) 1.98
Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med (2008) 1.91
Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol (2008) 1.76
Prevention of venous thromboembolism. Chest (2005) 1.76
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood (2008) 1.65
Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol (2005) 1.56
The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood (2008) 1.55
Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol (2007) 1.50
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res (2006) 1.48
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost (2010) 1.47
Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost (2013) 1.47
Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med (2005) 1.43
VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis. J Clin Epidemiol (2006) 1.31
Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke (2012) 1.25
Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin (2007) 1.23
A review of the cost of cardiovascular disease. Can J Cardiol (2009) 1.20
Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood (2005) 1.10
Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol (2004) 1.07
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood (2008) 1.03
Changes in insulin resistance indicators, IGFs, and adipokines in a year-long trial of aerobic exercise in postmenopausal women. Endocr Relat Cancer (2011) 1.01
Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol (2003) 0.99
Using International Classification of Diseases, 10th edition, codes to estimate abusive head trauma in children. Am J Prev Med (2012) 0.97
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med (2007) 0.95
Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clinicoecon Outcomes Res (2011) 0.95
Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost (2009) 0.94
Mutations in the paralogous human alpha-globin genes yielding identical hemoglobin variants. Ann Hematol (2008) 0.93
Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med (2005) 0.93
Injury mortality rates in Native and non-Native children: a population-based study. Public Health Rep (2007) 0.92
Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clinicoecon Outcomes Res (2012) 0.92
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med (2009) 0.91
Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: a meta-analysis. Open Med (2007) 0.91
Case 1-2005: cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease. J Cardiothorac Vasc Anesth (2005) 0.89
Impaired therapeutic vasculogenesis by transplantation of OxLDL-treated endothelial progenitor cells. J Lipid Res (2006) 0.88
A review of health utilities across conditions common in paediatric and adult populations. Health Qual Life Outcomes (2010) 0.88
Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China. Health Qual Life Outcomes (2012) 0.88
Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura. Int J Hematol (2008) 0.88
Sample size calculations in randomized trials: common pitfalls. Can J Anaesth (2007) 0.88
The burden of atrial fibrillation on the hospital sector in Canada. Can J Cardiol (2012) 0.87
Prevalence of PSA testing and effect of clinical indications on patterns of PSA testing in a population-based sample of Alberta men. Chronic Dis Can (2002) 0.85
Economic appraisal of a community-wide cardiovascular health awareness program. Value Health (2013) 0.84
A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exons. Blood (2004) 0.83
Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost (2010) 0.83
Hyperbaric oxygen therapy for diabetic ulcers: systematic review and meta-analysis. Int J Technol Assess Health Care (2013) 0.83
Mesenchymal stem/stromal cells (MSC) transfected with stromal derived factor 1 (SDF-1) for therapeutic neovascularization: enhancement of cell recruitment and entrapment. Med Hypotheses (2007) 0.82
Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics (2003) 0.82
Photoselective vaporization for the treatment of benign prostatic hyperplasia. Ont Health Technol Assess Ser (2013) 0.81
Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med (2007) 0.81
A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics (2004) 0.80
Effects of an enhanced secondary prevention program for patients with heart disease: a prospective randomized trial. Can J Cardiol (2007) 0.80
Prevention of venous thromboembolism after ischemic stroke. Curr Opin Pulm Med (2008) 0.80
Endothelial progenitor cells transfected with PDGF: cellular and molecular targets for prevention of diabetic microangiopathy. Med Hypotheses (2006) 0.80
Prevention of diabetic microangiopathy by prophylactic transplant of mobilized peripheral blood mononuclear cells. Acta Pharmacol Sin (2007) 0.80
Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective. Expert Rev Pharmacoecon Outcomes Res (2011) 0.79
Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost (2009) 0.79
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost (2016) 0.78
Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing. Blood Coagul Fibrinolysis (2016) 0.78
The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost (2007) 0.78
Inter-observer reliability of measures to assess the post-thrombotic syndrome. Thromb Haemost (2008) 0.78
Association of autoantibodies to heat-shock protein 60 with arterial vascular events in patients with antiphospholipid antibodies. Arthritis Rheum (2011) 0.78
Conditionally funded field evaluations and practical trial design within a health technology assessment framework. J Am Coll Radiol (2009) 0.78
Pulmonary vascular disease. Curr Opin Pulm Med (2002) 0.77
Low oxygen saturation by pulse oximetry may be associated with a low oxygen affinity hemoglobin variant, hemoglobin Titusville. J Pediatr Hematol Oncol (2006) 0.77
Stroke prenotification is associated with shorter treatment times for warfarin-associated intracerebral hemorrhage. Cerebrovasc Dis (2013) 0.77
Health technology assessment and primary data collection for reducing uncertainty in decision making. J Am Coll Radiol (2009) 0.77